Development of an updated, standardized, patient-centered outcome set for lung cancer

Belle H. de Rooij*, Corina van den Hurk, Veerle Smaardijk, Paz Fernandez-Ortega, Arturo Navarro-Martin, Lidia Barberio, Matthias Guckenberger, Severin Schmid, Iris Walraven, Susan Vallow, Christina Kotsi, Matthias Preusser, Erika Mosor, Jente M. Klok, Annemarie Becker, Alessandra Milani, Lyudmil Ninov, Lonneke V. van de Poll-Franse

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: In 2016, the International Consortium for Health Outcomes Measurement (ICHOM) defined an international consensus recommendation of the most important outcomes for lung cancer patients. The European Health Outcomes Observatory (H2O) initiative aimed to develop an updated patient-centered core outcome set (COS) for lung cancer, to capture the patient perspective of the impact of lung cancer and (novel) treatments using a combination of patient-reported outcome (PRO) instruments and clinical data as a means to drive value-based health-care. Material and methods: An international, expert team of patient representatives, multidisciplinary healthcare professionals, academic researchers and pharmaceutical industry representatives (n = 17) reviewed potential outcomes generated through literature review. A broader group of patients/patient representatives (n = 31), healthcare professionals / academic researchers (n = 83), pharmaceutical industry representatives (n = 26), and health authority representatives (n = 6) participated in a Delphi study. In two survey rounds, participants scored the relevance of outcomes from a preliminary list. The threshold for consensus was defined as ≥ 70 % of participants scoring an outcome as ‘highly relevant’. In concluding consensus-meeting rounds, the expert multidisciplinary team finalized the COS. Results: The preliminary list defined by the core group consisted of 102 outcomes and was prioritized in the Delphi procedure to 64. The final lung cancer COS includes: 1) case-mix factors (n = 27); 2) PROs related to health-related quality of life (HRQoL) (n = 25); 3) clinical outcomes (n = 12). Patient-reported symptoms beyond domains included in the ICHOM lung cancer set in 2016 were insomnia, nausea, vomiting, anxiety, depression, lack of appetite, gastric problems, constipation, diarrhoea, dysphagia, and haemoptysis. Conclusions: We will implement the lung cancer COS in Europe within the H2O initiative by collecting the outcomes through a combination of clinician-reported measures and PRO measures. The COS will support the adoption and reporting of lung cancer measures in a standardized way across Europe and empower patients with lung cancer to better manage their health care.

Original languageEnglish
Pages (from-to)5-13
Number of pages9
JournalLung Cancer
Volume173
DOIs
Publication statusPublished - Nov 2022

Bibliographical note

Publisher Copyright: © 2022 The Authors

Fingerprint

Dive into the research topics of 'Development of an updated, standardized, patient-centered outcome set for lung cancer'. Together they form a unique fingerprint.

Cite this